167 related articles for article (PubMed ID: 36870042)
1. Cemiplimab as Second-Line Therapy for Patients with Recurrent Cervical Cancer: A United States-based Cost-effectiveness Analysis.
Liu K; Zhu Y; Zhou Y; Zhu H
Adv Ther; 2023 Apr; 40(4):1838-1849. PubMed ID: 36870042
[TBL] [Abstract][Full Text] [Related]
2. First-line Cemiplimab versus Standard Chemotherapy in Advanced Non-small Cell Lung Cancer Patients with at Least 50% Programmed Cell Death Receptor Ligand-1 Positivity: Analysis of Cost-effectiveness.
Zhang M; Liu X; Wen F; Wu Q; Zhou K; Bai L; Li Q
Clin Oncol (R Coll Radiol); 2022 Mar; 34(3):e123-e129. PubMed ID: 34736841
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Cemiplimab Versus Chemotherapy as First-Line Treatment in Advanced NSCLC with PD-L1 Expression Levels of at Least 50.
Wang L; Peng Y; Zeng X; Peng L; Li S; Qin S; Wan X; Tan C
Adv Ther; 2021 Aug; 38(8):4354-4365. PubMed ID: 34241780
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Cemiplimab Versus Standard of Care in the United States for First-Line Treatment of Advanced Non-small Cell Lung Cancer With Programmed Death-Ligand 1 Expression ≥50.
Kuznik A; Smare C; Chen CI; Venkatachalam M; Keeping S; Atsou K; Xu Y; Wilson F; Guyot P; Chan K; Glowienka E; Konidaris G
Value Health; 2022 Feb; 25(2):203-214. PubMed ID: 35094793
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.
Shi Y; Chen J; Shi B; Liu A
Gynecol Oncol; 2022 Feb; 164(2):379-385. PubMed ID: 34920886
[TBL] [Abstract][Full Text] [Related]
6. Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: A network meta-analysis and cost-effectiveness analysis.
Li Y; Liang X; Yang T; Guo S; Chen X
Front Oncol; 2022; 12():878054. PubMed ID: 36226060
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC.
Wan N; Zhang TT; Hua SH; Lu ZL; Ji B; Li LX; Lu LQ; Huang WJ; Jiang J; Li J
Cancer Med; 2020 Mar; 9(5):1683-1693. PubMed ID: 31945265
[TBL] [Abstract][Full Text] [Related]
8. Pembrolizumab with or without bevacizumab for recurrent or metastatic cervical cancer: A cost-effectiveness analysis.
Barrington DA; Riedinger C; Haight PJ; Tubbs C; Cohn DE
Gynecol Oncol; 2022 Jun; 165(3):500-505. PubMed ID: 35422338
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of pembrolizumab plus chemotherapy for patients with recurrent or metastatic cervical cancer in China.
Zheng Z; Song X; Qiu G; Xu S; Cai H
Curr Med Res Opin; 2023 Mar; 39(3):433-440. PubMed ID: 36757780
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab Plus Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A Cost-Effectiveness Analysis.
Zhu Y; Liu K; Ding D; Zhou Y; Peng L
Adv Ther; 2022 Jun; 39(6):2614-2629. PubMed ID: 35394255
[TBL] [Abstract][Full Text] [Related]
11. Avelumab Maintenance Treatment After First-line Chemotherapy in Advanced Urothelial Carcinoma-A Cost-Effectiveness Analysis.
Lin D; Luo S; Lin S; Zhong L; Zhou W; Gu D; Huang X; Chen Q; Xu X; Weng X
Clin Genitourin Cancer; 2023 Feb; 21(1):8-15. PubMed ID: 36328903
[TBL] [Abstract][Full Text] [Related]
12. First-Line ICI Monotherapies for Advanced Non-small-cell Lung Cancer Patients With PD-L1 of at Least 50%: A Cost-Effectiveness Analysis.
Liu Q; Zhou Z; Luo X; Yi L; Peng L; Wan X; Tan C; Zeng X
Front Pharmacol; 2021; 12():788569. PubMed ID: 34992538
[No Abstract] [Full Text] [Related]
13. First-Line Lenvatinib Plus Pembrolizumab or Everolimus versus Sunitinib for Advanced Renal Cell Carcinoma: A United States-Based Cost-Effectiveness Analysis.
Zhu Y; Liu K; Ding D; Peng L
Clin Genitourin Cancer; 2023 Jun; 21(3):417.e1-417.e10. PubMed ID: 36529626
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.
Peng Y; She Z; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Adv Ther; 2021 Dec; 38(12):5710-5720. PubMed ID: 34693504
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of pembrolizumab versus chemotherapy as first-line treatment in locally advanced or metastatic non-small cell lung cancer with PD-L1 tumor proportion score 1% or greater.
She L; Hu H; Liao M; Xia X; Shi Y; Yao L; Ding D; Zhu Y; Zeng S; Shen L; Huang J; Carbone DP
Lung Cancer; 2019 Dec; 138():88-94. PubMed ID: 31655368
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of cemiplimab vs pembrolizumab for treatment of advanced cutaneous squamous cell carcinoma.
Paul E; Konidaris G; Cope S; Chen CI; Keeping S; Xu Y; Atsou K; Ayers D; Guyot P; Sasane M; Mojebi A; Kuznik A
J Manag Care Spec Pharm; 2021 Nov; 27(11):1513-1525. PubMed ID: 34351214
[No Abstract] [Full Text] [Related]
17. Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer.
Lin YT; Wang C; He XY; Yao QM; Chen J
Front Immunol; 2023; 14():1345942. PubMed ID: 38274823
[TBL] [Abstract][Full Text] [Related]
18. Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.
Lang Y; Lin Y; Deng M; Liu X
BMC Cancer; 2024 Feb; 24(1):236. PubMed ID: 38383374
[TBL] [Abstract][Full Text] [Related]
19. Cemiplimab combined with chemotherapy
Zhu G; Cai H; Zheng Z
Ther Adv Med Oncol; 2023; 15():17588359231213619. PubMed ID: 38028144
[TBL] [Abstract][Full Text] [Related]
20. First-Line Atezolizumab for Metastatic NSCLC with High PD-L1 Expression: A United States-Based Cost-Effectiveness Analysis.
Peng Y; Zeng X; Peng L; Liu Q; Yi L; Luo X; Li S; Wang L; Qin S; Wan X; Tan C
Adv Ther; 2021 May; 38(5):2447-2457. PubMed ID: 33821431
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]